HGU Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain.
Hospital Universitario Germans Trias i Pujol, Badalona, Spain.
Clin Transl Oncol. 2019 Aug;21(8):1044-1051. doi: 10.1007/s12094-018-02021-7. Epub 2019 Jan 7.
The clinical course in patients with prostate cancer (PCa) after biochemical failure (BF) has received limited attention. This study analyzes survival time from recurrence, patterns of progression, and the efficacy of salvage therapies in patients treated with radical or postoperative radiotherapy (RT).
This is a multicenter retrospective comparative study of 1135 patients diagnosed with BF and treated with either radical (882) or postoperative (253) RT. Data correspond to the RECAP database. Clinical, tumor, and therapeutic characteristics were collected. Descriptive statistics, survival estimates, and comparisons of survival rates were calculated.
Time to BF from initial treatment (RT or surgery) was higher in irradiated patients (51 vs 37 months). At a median follow-up of 102 months (14-254), the 8-year cause-specific survival (CSS) was 80.5%, without significant differences between the radical (80.1%) and postoperative (83.4%) RT groups. The 8-year metastasis-free survival rate was 57%. 173 patients (15%) died of PCa and 29 (2.5%) of a second cancer. No salvage therapy was given in 15% of pts. Only 5.5% of pts who underwent radical RT had local salvage treatment and 71% received androgen deprivation (AD) ± chemotherapy. The worst outcomes were in patients who developed metastases after BF (302 pts; 26.5%) and in cases with a Gleason > 7.
In PCa treated with radiotherapy, median survival after BF is relatively long. In this sample, no differences in survival rates at 8-years have been found, regardless of the time of radiotherapy administered. AD was the most common treatment after BF. Metastases and high Gleason score are adverse variables. To our knowledge, this is the first study to compare outcomes after BF among patients treated with primary RT vs. those treated with postoperative RT and to evaluate recurrence patterns, treatments administered, and causes of death. The results allow avoiding overtreatment, improving quality of life, without negatively affecting survival.
前列腺癌(PCa)患者生化复发(BF)后的临床病程受到的关注有限。本研究分析了接受根治性或术后放疗(RT)治疗的患者的复发后生存时间、进展模式和挽救治疗的疗效。
这是一项多中心回顾性比较研究,纳入了 1135 名诊断为 BF 并接受根治性(882 例)或术后(253 例)RT 治疗的患者。数据来自 RECAP 数据库。收集了临床、肿瘤和治疗特征。计算了描述性统计、生存估计和生存率比较。
与接受放疗的患者相比,初始治疗(RT 或手术)后的 BF 时间更高(51 个月比 37 个月)。在中位随访 102 个月(14-254)后,8 年的特异性生存(CSS)为 80.5%,根治性(80.1%)和术后(83.4%)RT 组之间无显著差异。8 年无转移生存率为 57%。173 例(15%)患者死于 PCa,29 例(2.5%)死于第二癌症。15%的患者未接受挽救治疗。仅 5.5%接受根治性 RT 的患者接受了局部挽救治疗,71%接受了雄激素剥夺(AD)±化疗。预后最差的是 BF 后发生转移的患者(302 例;26.5%)和 Gleason 评分>7 的患者。
在接受放疗的 PCa 患者中,BF 后的中位生存时间相对较长。在本样本中,无论 RT 治疗时间如何,8 年生存率均无差异。AD 是 BF 后最常见的治疗方法。转移和高 Gleason 评分是不良变量。据我们所知,这是第一项比较原发 RT 治疗与术后 RT 治疗的患者 BF 后结局的研究,并评估了复发模式、治疗方法和死亡原因。结果可以避免过度治疗,提高生活质量,而不会对生存产生负面影响。